Cangrelor  (Synonyms: AR-C69931MX)

Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist^[1][2].

P2Y12, GPR17^[1][2]

Cangrelor tetrasodium has pK_b of 8.6-9.2 for hP2Y12 receptor^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

776.36

C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂

163706-06-7

CSCCNC1=C2C(N([C@H]3[C@H](O)[C@H](O)[C@@H](COP(OP(C(Cl)(Cl)P(O)(O)=O)(O)=O)(O)=O)O3)C=N2)=NC(SCCC(F)(F)F)=N1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.